On Mar. 31, 2020, Emergent BioSolutions announced an agreement with Novavax whereby Emergent will provide molecule-to-market contract development and manufacturing services to produce Novavax’s NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M- adjuvant.